Connect:        


All Releases
View Summary Intellipharmaceutics Announces Resignation of Chief Financial Officer
Aug 8, 2017
PDF 18.8 KB Add to Briefcase
View Summary Intellipharmaceutics Intends to Vigorously Defend Recently Filed Purported Class Action Lawsuit
Jul 31, 2017
PDF 19.8 KB Add to Briefcase
View Summary Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Rexista™ (oxycodone hydrochloride extended release), an Abuse-Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain
Jul 26, 2017
PDF 22.6 KB Add to Briefcase
View Summary Intellipharmaceutics Announces Second Quarter 2017 Results
Jul 11, 2017
PDF 41.8 KB Add to Briefcase
View Summary Intellipharmaceutics Announces FDA Advisory Committee Meeting for Rexista™ (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain
Jun 30, 2017
PDF 22.4 KB Add to Briefcase
View Summary Intellipharmaceutics Announces Launch of Generic Seroquel XR® by Mallinckrodt
Jun 6, 2017
PDF 20.3 KB Add to Briefcase
View Summary Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement to Replace Expiring Shelf Registration Statement
May 26, 2017
PDF 20.9 KB Add to Briefcase
View Summary Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical
May 24, 2017
PDF 20.6 KB Add to Briefcase
View Summary Intellipharmaceutics Announces FDA Final Approval of Generic Seroquel XR®
May 10, 2017
PDF 21.5 KB Add to Briefcase
View Summary Intellipharmaceutics Reports Director Election Results
Apr 18, 2017
PDF 19.9 KB Add to Briefcase
View Summary Intellipharmaceutics Announces First Quarter 2017 Results
Apr 11, 2017
PDF 42.7 KB Add to Briefcase
View Summary Intellipharmaceutics Announces Patent Litigation by Purdue against its Rexista™ Abuse-Deterrent Extended-Release Oxycodone
Apr 10, 2017
PDF 19.6 KB Add to Briefcase
View Summary Intellipharmaceutics Announces TSX Trading Symbol Change to "IPCI"
Mar 16, 2017
PDF 18.3 KB Add to Briefcase
View Summary Intellipharmaceutics Announces FDA Approval for 500 mg and 750 mg Generic Glucophage® XR
Feb 24, 2017
PDF 19.5 KB Add to Briefcase
View Summary Intellipharmaceutics Announces 2016 Year End Results
Feb 10, 2017
PDF 48.0 KB Add to Briefcase
View Summary Intellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista™ (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain
Feb 2, 2017
PDF 21.5 KB Add to Briefcase
View Summary Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical
Jan 6, 2017
PDF 18.9 KB Add to Briefcase
View Summary Intellipharmaceutics to Present at the Biotech Showcase™
Dec 29, 2016
PDF 17.6 KB Add to Briefcase
View Summary Intellipharmaceutics Announces Issuance of U.S. and Canadian Patents Covering Aspects of its PODRAS™ Overdose Technology
Dec 21, 2016
PDF 20.8 KB Add to Briefcase
View Summary Intellipharmaceutics to Present at the LD Micro Main Event
Nov 29, 2016
PDF 17.7 KB Add to Briefcase
Showing 1-20 of 152 Page: 1 2 3 ... 8  Next 20
=add release to Briefcase